Moderna pens deal with China to make mRNA medicines that 'will not be exported'

Lei Lei Wu

News Reporter

Moderna signed a deal Wednesday to develop and manufacture mRNA medicines in China, after other US and European Covid-19 drugmakers struggled to break into the market without a Chinese partner.

Under the agreement, the Cambridge, MA vaccine developer will produce medicines in China that “will be exclusively for the Chinese people” and “will not be exported,” according to an emailed statement from Moderna.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Moderna pens deal with China to make mRNA medicines that 'will not be exported'

Lei Lei Wu

News Reporter

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Mod­er­na pens deal with Chi­na to make mR­NA med­i­cines that 'will not be ex­port­ed'

Lei Lei Wu

News Reporter

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

As­traZeneca pulls Covid-19 vac­cine glob­al­ly as the phar­ma sees 'no fu­ture com­mer­cial de­mand'

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Moderna pens deal with China to make mRNA medicines that 'will not be exported'

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

Medical Affairs: The Critical Link Between Science, Physicians and Patients